Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).

2 Jul 2014

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

9 Jun 2014

New compound restores learning, memory and other symptoms of AD in mice

A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease.

21 May 2014

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).

21 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Isis Pharmaceuticals, Inc. announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.

15 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Genzyme, Isis receive 2014 Partners in Progress Corporate Award for KYNAMRO injection

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO (mipomersen sodium) injection.

9 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals, Inc. announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.

2 May 2014

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy.

17 Apr 2014

Novel discovery could lead to new therapy to combat obesity, diabetes

By manipulating a biochemical process that underlies cells' energy-burning abilities, investigators at Beth Israel Deaconess Medical Center have made a novel discovery that could lead to a new therapy to combat obesity and diabetes.

10 Apr 2014

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).

2 Apr 2014

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

24 Mar 2014

Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today reported financial results for the three months and year ended December 31, 2013, and provided an update of recent corporate developments.

27 Feb 2014

Isis Pharmaceuticals provides update on ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).

25 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

Researchers discover new gene involved in severe childhood epilepsy

A European consortium of epilepsy researchers has reported the discovery of a new gene involved in severe childhood epilepsy. Using a novel combination of technologies, including trio exome sequencing of patient/parental DNA and genetic studies in the tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found that mutations in the gene CHD2 are responsible for a subset of epilepsy patients with symptoms similar to Dravet syndrome - a severe form of childhood epilepsy that is in many patients resistant to currently available anti-epileptic drugs.

23 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014